Anticardiolipin and anti-beta2-glycoprotein-I antibodies in preeclampsia
Lee, R.M.; Brown, M.A.; Branch, D.Ware.; Ward, K.; Silver, R.M.
Obstetrics and Gynecology 102(2): 294-300
2003
ISSN/ISBN: 0029-7844 PMID: 12907102 Document Number: 561369
OBJECTIVE: To estimate whether antiphospholipid antibodies, specifically anticardiolipin and anti-beta2-glycoprotein-I antibodies, are associated with preeclampsia. METHODS: Plasma was prospectively obtained from four groups of pregnant women: those with 1) mild preeclampsia (n=109); 2) severe preeclampsia (n=134); 3) hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome (n=57); and 4) normotensive controls (n=100). Anticardiolipin and anti-beta2-glycoprotein-I levels were determined by enzyme-linked immunoassay. RESULTS: Subjects with mild preeclampsia, severe preeclampsia, and HELLP syndrome did not have significantly elevated levels of immunoglobulin G (IgG) and IgM anticardiolipin and anti-beta2-glycoprotein-I antibodies compared with normotensive controls (P>.05, Kruskal-Wallis). Similarly, subjects with mild preeclampsia, severe preeclampsia, and HELLP syndrome did not have a significantly higher proportion of women testing positive for each autoantibody compared with normotensive controls (chi2). The proportion of patients testing positive for anticardiolipin and anti-beta2-glycoprotein-I antibodies were similar in patients with preeclampsia developing before and after 34 weeks' gestation (chi2). CONCLUSION: Circulating levels of both anticardiolipin and anti-beta2-glycoprotein-I antibodies were not increased in patients with mild preeclampsia, severe preeclampsia, or HELLP syndrome compared with normotensive controls. Our data do not support routine testing for anticardiolipin and anti-beta2-glycoprotein-I antibodies in women with preeclampsia.